SUTRO BIOPHARMA, INC.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
STRO$10.61+10.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Comprehensive Loss
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Net loss | $(191,086) | $(227,461) |
| Other comprehensive income (loss): | ||
| Net unrealized income (loss) on available-for-sale securities | (20) | 18 |
| Comprehensive loss | $(191,106) | $(227,443) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.